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Summary Bronchial hyper-reactivity (BHR) has been suggested to follow cessation
of regular medication with racemic salbutamol. This study aimed at investigating the
effects from medication with R,S- and R-salbutamol on bronchial response to
provocation with isocapnic hyperventilation of cold air (IHCA).
Twenty-six patients with mild to moderate asthma were enrolled in a double-
blind, randomised, cross-over study. Bronchial response to provocation was
measured before and after 1 week’s medication. Doses of 0.63mg R-salbutamol or
1.25mg R/S-salbutamol were inhaled three times daily during medication-weeks and
a wash-out week intervened. Tests were performed 6 h after the last dose of test
drug. Impulse oscillometry and forced expiratory volume during one second were
methods used to identify bronchial response to provocation. Two patients withdrew
from the investigation due to side-effects, one from R- the other from R,S-
salbutamol.
Comparable resting bronchial conditions were indicated by differences in baseline
lung function values of o2% between study days. No statistically significant
medication-dependent differences in BHR could be demonstrated between treat-
ment groups. However, 15 patients exhibited higher (P ¼ 0:03) post-treatment BHR
after pure R-salbutamol than after R,S-salbutamol. Furthermore, plasma concentra-
tions of R-salbutamol tended to be lower (P ¼ 0:08) after medication with R- than
after R,S-salbutamol despite equal doses of R-salbutamol given during the two
separate treatment periods. We also found that considerable amounts of
S-salbutamol were retrieved in plasma after medication with pure R-salbutamol.
We conclude that we were unable to demonstrate favourable effects of
R-salbutamol over R,S-salbutamol regarding response to provocation with IHCA
after regular medication of 1 week’s duration.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Asthma is characterised by airway inflamma-
tion, variable airway constriction and abnormal
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bronchial responses to various stimuli, i.e. bron-
chial hyperresponsiveness (BHR). It is assumed that
bronchodilatation and BHR are effected via differ-
ent mechanisms. Bronchodilatation may be the
result of beta-2-receptor stimulation as induced by
a beta-2-receptor agonist.1 The bronchodilating
properties of Salbutamol, a racemic beta-2-recep-
tor agonist, follow the R-enantiomer. The racemate
undergoes stereoselective inactivation in man
through sulphation by sulphotransferases, mainly
in the gut and liver. Bronchodilating R-salbutamol
undergoes faster and up to 10-fold more effective
metabolism than the S-enantiomer, leading to S/R-
salbutamol ratios in serum exceeding one. Re-
peated administrations of racemate may lead to
accumulation of S-salbutamol2 and after cessation
of bronchodilation, accomplished by R,S-salbuta-
mol, a distinguishable amount of S-salbutamol can
still be found in plasma.
BHR may be the result of converging factors or
cascades3,4 and might also be mediated via
unknown mechanisms and also suggested to corre-
late with genetic variability of the beta-2-receptor
gene.5 A pro-inflammatory effect has been sug-
gested to occur following cessation of medication
with racemic salbutamol, reflected by accumula-
tion of eosinophils6 as well as enhanced BHR.7,8 This
has been proposed to be connected with S-
salbutamol,9,10 suggesting a stereoselective pro-
inflammatory effect. In contrast, both R- and S-
enantiomers of another beta-receptor-agonist, iso-
prenaline, has been suggested to increase airway
hyperreactivity in guinea pigs.11,12 The connection
between BHR and presence of S-salbutamol in man
is under debate, and a relation between S-
salbutamol levels in serum and lung-physiology
has until now not been demonstrated in humans.
The aim of this study was to evaluate whether
bronchial responsiveness elicited by isocapnic
hyperventilation of cold air (IHCA) would increase
after repeated dosing during 1 week with R,S-
salbutamol relative to corresponding treatment
with pure R-salbutamol. Provided that adequate
plasma levels of S-enantiomer are still present and
that masking of BHR by remaining bronchodilation
exerted by R-salbutamol is not at hand, enhanced
BHR would indirectly suggest the S-enantiomer to
be associated with post-treatment increases of
BHR. Based on previous findings,2 such prerequi-
sites were presumed to occur not earlier than 6 h
after a final dose of R,S-salbutamol.
Apart from tests on BHR to IHCA, values of
eosinophil cationic protein (ECP) in serum were
taken as an estimate of eosinophil related inflam-
mation and used as a secondary endpoint. Genetic
variability at amino acid 16 and 27 of the beta-2-
receptor gene has been shown to be linked with
characteristics of asthma.13,14 Possible associations
between drug induced BHR and polymorphisms of
the beta-2-receptor gene (Gly16 and Glu 27) or
salbutamol metabolising enzyme gene (SULT 1A3)
were studied.
Materials and methods
Patients
Twenty-six patients with mild to moderate asthma
were selected, as a consequence of distinctly
identifiable bronchial reactivity to IHCA, from a
pool of 36 patients with a history of asthma.
Fourteen out of 26 were female and 20 of the
patients were allergic, mostly to common aero-
allergens or animal dander. Demographic data are
presented in Table 1.
Criteria for inclusion were asthma according to
GINA criteria15 and a significant response to
provocation, i.e. X30% increase of total airway
resistance as measured by impulse oscillometry
(IOS). Patients with more than 800micrograms (mg)
daily of inhaled budesonide or corresponding
amounts of other inhaled steroids or any oral
steroids were not included in this study. Patients
should not have been suffering from any other
serious condition beside asthma. Prior to any test,
short acting beta-agonists other than study-medi-
cation were not allowed or if used on an ‘‘as
required basis’’ it was withheld for at least 8 h, long
acting beta-agonists for 24 h, leucotriene-receptor
antagonists for 3 days and antihistamines for 1
week. Fourteen of our patients were on regular
inhaled budesonide in doses ranging between 200
and 800 mg daily. This medication was allowed
unchanged throughout the study. Two patients
withdrew from the study after inclusion due to
side effects, one (No. 1, Table 1) with worsening of
asthma with nightly wheezes during medication
with R,S-salbutamol, and the other (No. 10) with
troublesome palpitations during medication with R-
salbutamol.
All patients gave written informed consent
before entering the study that was approved by
the Medical Products Agency, Sweden and the
Ethics Research Committee, Faculty of Health,
University of Link .oping, Sweden.
Study design
Patients were enrolled in a double blind, rando-
mised, crossover study including medication with
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R-salbutamol (Xopenexs, Sepracor Inc., Marlbor-
ough, MA, USA) and R,S-salbutamol (Ventolines,
GlaxoSmithKline, M .olndal, Sweden), and test for
BHR before and after study treatments as outlined
in Fig. 1. During the study-period each patient
reported for testing five times with 6–8 day
intervals. At the first visit, a history of asthma
and allergy was obtained and a brief medical
examination was performed for each person before
entering the study. A run-in week with twice daily
peak expiratory flow (PEF) measurements, revealed
stable conditions with PEF variability below 10% in
all patients. Randomisation to medication during 1
week with either R- or R,S-salbutamol was done at
the second visit, using a pre-designed randomisa-
tion list. During study-weeks two and four, only the
test drugs (i.e., R-salbutamol or R,S-salbutamol,
respectively) was allowed as rescue medication. To
avoid masking of BHR by remaining bronchodila-
tion, tests and provocation at the end of medica-
tion-weeks were performed 6 h after the last dose
of either medication. A wash-out period of more
than 6 days, corresponding to more than 20 times
the half-life of S-salbutamol16 was carried out
during the third study week.
Each visit started with blood-sampling for analy-
sis of ECP in serum and salbutamol-isomers in
plasma as well as control of bronchial status. After
challenge by means of IHCA, IOS was measured at
every second minute for a period of 8min and FEV1
was assessed 10min after the challenge. All
medication used during the four study-weeks was
documented by the patients in a medication-diary
that was scrutinised by one researcher (KNS) to
confirm adherence to protocol. Evaluation of all
results was performed blinded to medication.
Lung function tests
Bronchial status was studied with IOS via an MS-IOS
Digital instrument (Erich Jaeger AG, W .urzburg,
Germany) attached to a computer. Resistance at
5Hz (R5) was defined to represent total airway
resistance, and resistance at 20Hz (R20) to reflect
status in the central airways. Baseline values of
these parameters were determined as the mean of
two values measured during tidal breathing before
provocation. Reactance at 5Hz (X5) and resonant
frequency (Fres)Fthe frequency where reactance
is zeroFwere also documented. IOS-values were
obtained before and at 2, 4, 6 and 8min after
bronchial provocation. Artefacts from the upper
airways were minimised by manual control, a firm
pressure of cheek and chin, and reproducibility of
bronchial status ascertained by two consecutive
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Table 1 Demographic data for patients in this
study.
Pat.
no.
Age
(years)
Sex
(F/M)
BMI
(kg/cm2)
Allergy Reg.
med.
FEV1
(% pred)
1a 50 M 30 F a,b 102
2 23 F 25 þ F 84
3 54 M 27 þ a,b 95
4 55 F 28 þ p a 100
5 33 F 28 þ p a,d 88
6 58 M 28 F a 76
7 25 F 24 þ p 100
8 34 F 30 þ p a,b 87
9 28 M 21 þ p 100
10a 29 M 23 þ a,b 122
11 56 F 40 F a,b 74
12 48 F 39 F F 88
13 20 F 21 þ p a 100
14 20 M 25 þ p F 100
15 51 M 24 þ F 97
16 40 F 33 þ p a 131
17 23 M 30 F F 90
18 29 F 19 F a 94
19 37 M 23 þ b,d 102
20 19 F 24 þ p a 107
21 38 F 36 þ p a,b 102
22 37 F 28 þ p F 111
23 25 M 33 þ p a,b,e 97
24 38 M 31 þ p a,b 136
25 30 M 35 þ p F 100
26 59 F 34 þ a,b 116
95% CI 32–43 F 26–31 F F 90–102
Females (F) and males (M), body mass index (BMI). Allergy
according to case history: non-pollen allergy¼ þ and
pollen allergy¼ þp. Regular medication (Reg. med.):
a¼ inhaled glucocorticosteroids, b¼ long-acting beta
agonists, c¼ short-acting beta agonists, d¼ anti-hista-
mine, e¼ leukotriene-receptor antagonist. Forced ex-
piratory volume over 1 s (FEV1) expressed as percentage
of the predicted normal value.
aWithdrew due to side effects.
Figure 1 Outline of design of the study including five
visits (V1–V5) during 4 weeks. Lung function tests were
performed before and after a bronchial provocation by
IHCA in every visit. After a run-in week (W1) patients
with asthma were randomised during visit number two
(V2) to treatment of either R,S-salbutamol or R-salbuta-
mol during the 2nd and 4th week. A washout week (W2)
intervened.
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measurements with a week’s interval prior to
randomisation, with a difference in baseline-values
of R5 not exceeding 0.1 kPa/l/s.
Forced expiratory volume over 1 s (FEV1) was
performed before and at 10min after provocation.
Previously published reference values17 were used
and the better of two volumes, recorded before
provocation, defined as the baseline value.
Bronchial challenge
For a period of 4min, dry cold air, admixed with 5%
CO2, was delivered to the patients via a respiratory
heat exchange system (RHES, Erich Jaeger AG,
W .urzburg, Germany) and a one-way valve. Tem-
perature was maintained at 151C and minute-
volume set by a rotameter (Platon, Platon Parks
Viables, Hants, UK), corresponding to approxi-
mately 70% of maximal voluntary ventilation,
calculated by 25 FEV1. To attain comparable
dosing of cold air, a balloon on the inspiratory side
was to be emptied at every inspiration and a
breathing rate around 25/min. encouraged. Bron-
chial responsiveness to IHCA was calculated as the
maximal percentage rise from baseline in R5 and
BHR was defined by a rise in R5 of at least 30% of
the baseline value. A rise in R5 exceeding a rise in
R20 was taken as being an indirect indicator of
events in the peripheral airways.
Medication
During medication-weeks 3ml of equipotent doses
of either R-salbutamol (Xopenexs, Sepracor Inc.,
Marlborough, MA, USA) 0.63mg/3ml or racemic
R,S-salbutamol (Ventolines, GlaxoSmithKline, M-
.olndal, Sweden) 1.25mg/3ml were inhaled three
times daily via a jet nebuliser (PARI Turbo BOY
attached to PARI LC, PARI GmbH, Starnberg,
Germany). Rescue doses of the same medication
were provided and allowed. Doses were delivered
in individual ampoules, prepared by the research-
laboratory at the Hospital Pharmacy (J.J. Berzelius,
University Hospital, Link .oping, Sweden). Xopenex
was kept in its original ampoules with the name
safely covered and Ventoline was diluted to the
desired strength at the pharmacy during strictly
sterile conditions. Left over doses were returned to
the pharmacy and were counted there. Study
subjects and experimenters were blinded to type
of medication throughout the study period.
Pollen
Pollen profiles were continuously obtained for the
region and time of interest (The Palynological
Laboratory, Swedish Museum of Natural History,
Stockholm, Sweden).
Assay of ECP
Venous blood was drawn and kept at room
temperature for 60715min, and then centrifuged
at 3000 rpm for 10min. The supernatant was stored
at 701 until analysed as previously described.18
Assay of isomers
Samples of venous blood were collected in 7ml
heparinised glass tubes (Vacutainer, Becton Dick-
inson and Co, Rutherford, NJ, USA) and centrifuged
(3000 rpm for 10min) within 45min after collec-
tion. The supernatant plasma was separated and
stored at 701 until analysis. Analysis of R- and S-
salbutamol was carried out by means of a stereo-
selective high performance liquid chromatography
assay (HPLC) with fluorescence detection, as
previously described.19
Genotyping
Allele frequencies for the normal population was
determined from DNA isolated from white blood
cells, from 206 individuals randomly collected in
the south-eastern region of Sweden, representing
the same study base as the asthma patients. The
two polymorphisms in the b2-adrenergic receptor,
GGA164AGA and CAA274GAA (Gly4Arg and
Gln4Glu, respectively) were determined by direct
DNA sequencing in both sense and anti-sence
direction, using fluorescently labelled dideoxy
terminators in a Megabase (Amersham-Pharmacia)
capillary sequencer. Polymorphic sites in the two
different isoforms of sulphotransferases (SULT),
1A1 and 1A2 were analysed according to published
methods based on PCR-restriction fragment length
polymorphism (RFLP).20,21 SULT1A3 displays two
polymorphic sites in close proximity to each other
in exon 7; CAC1434TAC (His4Tyr) and GAA1464G-
CA. We therefore choose the method of pyrose-
quencing22 to analyse both these genetic variants
simultaneously.
Statistics
Mean and 95% confidence intervals (95%CI) were
used to describe data, unless otherwise stated. T-
test for dependent or independent samples and
Mann–Whitney U-test were used in the statistical
evaluations, performed by a commercially avail-
able program (Statistica 6.0, Statsoft Inc, Tulsa,
OK, USA).
Sample size was chosen to give 90% power to
detect a 50% difference in mean responses (as delta
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R5) assuming a common standard deviation of
0.2 kPa/l/s. These data were based on earlier
studies. The power calculation was made by means
of a commercially available computer program
(nQuery Adviser 3.0, Statistical Solutions, Saugus,
MA, USA).
Results
Stable pre-challenge bronchial conditions were
recorded in all patients on the five different study
days, and there were no statistically significant
differences over time in baseline values obtained
before any challenge, whether seen as IOS-mea-
surements or FEV1 (P40:05 and 0:05; respectively,
Table 2).
IHCA elicited approximately four times larger
increases of values of R5 than of R20 (mean
increases of R5 ranged from 0.21 to 0.24 kPa/l/s
as compared to mean increases of R20 ranging from
0.05 to 0.06 kPa/l/s, Fig. 2) in all test-days.
Bronchial responses to provocation through hyper-
ventilation of cold air, were similar on all 3 days not
preceded by study medication, and did not differ
significantly from the days after 1 week of medica-
tion with either R- or R,S-salbutamol (Table 3). The
increases of R5 remained for at least 8min after
completion of the hyperventilation challenge, and
there were no significant differences between
values of R5 recorded at 8min after challenge
after either treatment or non-treatment weeks
(P40:05; all comparisons, data not shown). Nor
were there any differences in FEV1 recorded 10min
after IHCA.
The spread of data on post-challenge increases of
R5 however tended to be higher after treatment
with pure R-salbutamol than after R,S-salbutamol-
or after non-treatment weeks. After each treat-
ment-session (R- followed by R,S-salbutamol or
reverse) nine of 24 patients displayed a lessened
response to challenge whereas 15 of 24 patients of
each treatment group showed an increased re-
sponse relative to the day before commencement
of medication. There was no significant difference
between treatment groups when all values were
included for statistical evaluation. However, the
increase in bronchial reactivity after treatment
with R-salbutamol reached higher levels than
corresponding values in connection with R,S-salbu-
tamol (P ¼ 0:03; Fig. 3). Patients with attenuated
reactivity showed no such treatment-related dif-
ference (P ¼ 0:45). These observations were not
reflected in FEV1 readings. BHR recorded after each
treatment week was also compared with the
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individual values formed by the mean value of BHR
recorded after the three separate non-treatment
weeks (‘‘reference response’’). Airway responses
after R-salbutamol treatment were significantly
more pronounced than the ‘‘reference response’’
(P ¼ 0:04; paired analysis). In contrast airway
responses after R,S-salbutamol treatment were
similar to the reference values (P40:05).
Plasma-levels of isomers were measured at the
end of each medication week, 6 h after the latest
inhaled dose. Plasma concentrations of R-salbuta-
mol tended to be lower after regular use of pure R-
salbutamol than after R,S-salbutamol (0.13 ng/ml
(0.09–0.16) ng/ml vs. 0.10 (0.07–0.14) ng/ml, P ¼
0:08; paired analyses). When analysing data on an
individual basis, 18 of 24 samples showed lower
plasma levels of R-salbutamol after regular use of
R-salbutamol than after R,S-salbutamol (Fig. 4),
despite comparable doses of R-salbutamol taken
during 1 week. Plasma concentrations of S-salbu-
tamol significantly exceeded those of R-salbutamol
after treatment with racemic salbutamol (0.95 ng/
ml (0.68–1.22) ng/ml vs. 0.13 ng/ml (0.09–
0.16) ng/ml, Po0:001). Despite absence of detect-
able levels of any S-salbutamol in sample tests
performed on R-salbutamol batches delivered for
nebulisation, and no salbutamol taken prior to the
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Figure 2 Resistance at 5Hz (R5) and 20Hz (R20)
recorded in 24 patients with mild stable asthma. Data
recorded before and up to 8min after a 4min challenge
with isocapnic hyperventilation of dry cold air are given
(mean and standard error of mean are indicated). See
text for further information.
Table 3 Peak bronchial responses expressed as
percentage change from baseline in R5 and FEV1
after bronchial provocation through voluntary
isocapnic hyperventilation of cold air.
Change in
R5 (%)
Change in
FEV1 (%)
Before treatment
Screening test 66 (50–82) 10 (15 to 4)
Visit 2 65 (53–77) 9 (12 to 5)
Visit 4 60 (45–74) 8 (12 to 3)
After treatment
R,S- salbutamol 67 (54–86) 11 (15 to 7)
R-salbutamol 77 (55–100) 10 (14 to 6)
Measurements were made before and after 1 week’s
regular treatment with R-salbutamol or R,S-salbutamol.
Means (95%CIs) are given.
Figure 3 Values of bronchial response to provocation
(R5%) recorded before, subtracted from values recorded
after 1 week’s treatment with R,S-salbutamol (left panel)
and R-salbutamol (right panel). Positive values signify
greater reactivity after treatment than before. There
was no significant difference between treatment groups
when all values were included. Significantly higher
positive values (n ¼ 15 in each group; P ¼ 0:03) were
found after treatment with R-salbutamol than after R,S-
salbutamol. No significant difference was found between
treatment sorts in values below zero (n ¼ 9 in each
group; P ¼ 0:45).
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treatment week, significant amounts of S-salbuta-
mol were found in 15 of the 24 plasma samples
collected after 1 week’s treatment with R-salbuta-
mol (range 0.05–0.51 ng/ml).
Lower levels of R-salbutamol in plasma after
treatment with pure R-salbutamol, tended to be
associated with higher bronchial reactivity. Of 12
patients whose bronchial response to provocation
was more intense following R-salbutamol than
following R,S-salbutamol we found 10 to have
lower plasma levels of R-salbutamol after treat-
ment with pure R-salbutamol during 1 week than
after a R,S-salbutamol week.
There was no obvious association of bronchial
reactivity and plasma levels of S-salbutamol, and
although we did not design this study to assess
bronchodilatation as a result to treatment with
salbutamol enantiomers, we found no trace of
association between plasma levels of R-salbutamol
and bronchial tone as judged from R5 values at
baseline 6 h after the last inhaled dose. Nor did we
find that the order of treatments had any impact of
the results of either baseline lung function, BHR or
plasma concentration of R- or S-salbutamol, sug-
gesting no carry-over effect.
There were no statistically significant differences
in serum-ECP values from the five different days
(Table 2). Furthermore changes in pollen density
had no impact on serum values of ECP or lung
function whether lung function was expressed as
baseline lung function or as increases of resistance
after IHCA. Furthermore, plasma-levels of ECP
obtained at the start of every test-day did not
differ significantly between allergic and non-aller-
gic patients or between allergic patients who
reported for testing on days with low-versus on
days with high pollen-density in the air (Table 4).
Nor were there any differences in consumption of
rescue medication during wash out- or treatment
weeks (data not shown). Treatment with moderate
or low doses of inhaled corticosteroids had no
detectable impact on the results (data not shown).
The frequency of polymorphism of the Gly 16-
and Glu 27-alleles were 52% and 48%, respectively,
in the asthmatics as compared to 54% and 40%,
respectively, in control subjects. There were no
polymorphisms detected in SULT 1A-, 2 or 3- genes.
There were no obvious associations between any
detected polymorphism and/or clinical symptoms
that may have affected the drug response.
Discussion
We were unable to demonstrate any favourable
protecting effect of R-salbutamol over racemic
salbutamol following a week’s regular medication,
when effects were studied 6 h after cessation of
medication. This contradicts statements about the
superiority of medication with the single R-en-
antiomer and indirectly about a negative effect
from presence of S-salbutamol.23 On the contrary,
when only those medication-weeks that resulted in
enhanced reactivity were studied, or when results
were related to an individual reference response
formed by the average bronchial responses to IHCA
after the three separate non-treatment weeks,
medication over 1 week with R-salbutamol resulted
in more pronounced reactivity to provocation than
did 1 week’s medication with R,S-salbutamol.
We could not relate our findings of increased
susceptibility to IHCA to any confounding factor
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Figure 4 Levels in plasma of R-salbutamol (ng/ml) after
medication with R-salbutamol relative to after medica-
tion with R,S-salbutamol. Filled circles indicate indivi-
duals that displayed increased degree of bronchial
response to provocation after medication with R-salbu-
tamol.
Table 4 Serum concentrations of ECP obtained
before every bronchial provocation (n¼ number of
specimens).
n Median (lower–upper
quartile) (mg/l)
All 117 17.4 (12.5–24.9)
All, non-exposed 93 17.9 (12.6–24.4)
Allergic, non-exposed 50 19.6 (11.9–28.5)
Allergic, exposed 18 18.8 (12.6–29.3)
Median values (lower–upper quartile) are presented.
Allergic¼ specimen taken from a patient allergic to
pollen. Exposed¼ specimen taken on a day with high
pollen-density in the air. Data on three specimens are
missing due to technical errors.
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such as worsening in the asthmatic status or to
increased density of airborne pollen. Steroid-users
in this study did not differ from the cortisone-naive
individuals regarding our results, although steroid-
medication in previously ordered doses (not ex-
ceeding 800 mg/day) was allowed throughout the
study period. These findings may agree with
previous observations on hyperventilation chal-
lenge in patients treated with inhaled steroids.4,24
Our finding of minimal intra-individual variability of
IOS readings and serum ECP values as well as the
fact that almost no rescue medication was needed
during active treatment- or non-treatment weeks,
also suggests the asthmatic inflammation to be mild
in our patients. Since baseline lung function values
were almost identical when comparing data from
before treatment and at 6 h after completed
medication with R- or R,S-salbutamol, bronchial
dilatation was judged to have tailed off in all cases
and initial conditions to be comparable. We there-
fore conclude that masking of BHR by bronchodila-
tation was highly unlikely in our patients.
Interestingly, we could trace a connection be-
tween enhanced bronchial reactivity to IHCA and
signs of increased inactivation of R-salbutamol
after medication with the pure R-enantiomer.
Competition for salbutamol degrading enzymes
might possibly be one conceivable explanation for
abnormal metabolism of R-salbutamol when pure R-
salbutamol is used. Salbutamol is inactivated by
sulphotransferase 1A3,25 and any functional poly-
morphism of the SULT1A3 gene might result in
abnormal metabolism. Genotyping of the SULT1A3
gene did however not disclose any abnormality in
our patients. It is therefore implicated that addi-
tional, and up to now unknown, metabolic routes
may operate in metabolism of R-salbutamol. Since
both R- and S-salbutamol are metabolised by the
same sulphotransferases, theoretically, in the
absence of S-salbutamol, more R-salbutamol would
be inactivated by sulphation. Animal experiments
have pointed to the inhibition of contractile
responses in bronchi in connection with beta-
receptor-agonists, possibly as a result of modulated
release of tachykinins from airway sensory
nerves.26 The association to our results would then
theoretically be less beta-agonist (R-salbutamol)
available to influence bronchial contractions via
tachykinins. Less available R-salbutamol might also
have an impact on mediator-release from mastcells
and basophils and on the function of eosinophils
and basophils, thus leading to increased inflamma-
tory actions.26
Genetic polymorphism in the beta-2-receptor
gene leading to structural and functional variance
of the receptor has been suggested, including
differences in expression and down regulation of
the receptor. Conflicting results has been presented
and while polymorphisms in codons 16 and 27 have
been suggested to be associated with enhanced
bronchial responsiveness, others found no indivi-
dual polymorphism of codons 27 to be associated to
increased bronchial responsiveness.5,27,28 In con-
trast a protective effect was suggested to be
associated with the Gly16 or Gln27 haplotype.29
Receptor down regulation may occur after pro-
longed exposure of beta-2 agonists and the total
mass of available receptors is thereby decreased.
This has been associated with polymorphism of b2-
adrenoceptor with Glu at the 27 position.30 Poly-
morphism in codon 16 of the beta-2-receptor has
been shown to be associated to airway function in
asthmatics after regular treatment with an inhaled
beta-adrenergic agonist.14 We however found no
association between polymorphism in codon 16 or
27 of the beta-2-receptor gene and any clinical
feature in our patients with asthma.
Bronchial tone may be brought about by many
different means which is supposed to involve
various pathways of action. We chose an indirect
or non-specific test, IHCA, resembling a common-
day encounter. This test has high sensitivity and
specificity to identify asthmatics and does not give
noticeable bronchial constriction in a non-asth-
matic subject.4,31 An in-flow of cold air correspond-
ing to 70% of maximal ventilatory capacity was
arranged in our patients, by thorough instruction
and by supportive supervision during a 4min
challenge. Similarity in results from test days
following non-medication weeks gave us the con-
fidence to rely on results from the method as
performed.
It is recognized that results of bronchial provoca-
tion may depend on the method used for assess-
ment of effects. We chose IOS as a stable and
sensitive indicator for IHCA-induced bronchial
reactions.31 The main advantage lies in not having
to perform any extreme breathing efforts and
enabling serial evaluation of bronchial conditions
during tidal breathing. Any deep inspiration, such
as the one preceding a FEV1 manoeuvre, may have
an impact on the status within the respiratory
system32,33 This may be the reason why we did not
find parallel readings in IOS and FEV1 after
challenge. In agreement with earlier publications,
our measurements after IHCA showed changes in R5
that were considerably larger than changes in R20,
indicating that the rise in R5 reflects changes in the
peripheral airways.34
Both Fres and R5 are suggested to have high
sensitivity and specificity in identifying bronchial
obstruction by IHCA. Since we had the impression,
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in this study, that Fres-values swayed more than R5-
values we chose the latter as a stable and sensitive
indicator for bronchial reactions.
In conclusion we did not find support for the
proposed superiority in R-salbutamol over R,S-
salbutamol and neither, indirectly, for the suspicion
that presence of S-salbutamol would give rise to
diminished protection against bronchial hyper-
responsiveness or, indeed, increase in BHR. On the
contrary, a number of our patients had a more
pronounced response to IHCA after regular use of
the pure enantiomer R-salbutamol and the majority
of these patients had lower than expected plasma
levels of R-salbutamol after treatment with pure R-
salbutamol, suggesting enhanced metabolism of R-
salbutamol when given as a single isomer. These
data agree with previously published pharmacoki-
netic data.35 Furthermore, we found no genetic
polymorphism of the SULT 1A3 gene that could
explain altered metabolism. This suggests either a
lack of competition for metabolising enzymes or
perhaps that additional metabolic pathways for
degradation of salbutamol may exist in our
patients. We also found significant levels of S-
salbutamol in plasma after the treatment period
with pure R-salbutamol in some of our patients,
suggesting significant in vivo inter-conversion of
enantiomers. The fact that S-salbutamol is meta-
bolised much slower than R-salbutamol may have
augmented the increases of plasma levels of S-
salbutamol in a number of patients.
Theoretically results from a study population
consisting of a subgroup of asthma patients with
mild disease and reproducible bronchial responses to
IHCA might not be valid for a larger group of
asthmatics with severe disease. Further studies on
the effect of R-salbutamol in larger populations of
asthma patients with various phenotypic and geno-
typic characteristics, therefore seems warranted.
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